Patents Examined by Xiaozhen Xie
  • Patent number: 10328126
    Abstract: The present invention provides new protease-resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: June 25, 2019
    Assignee: Novartis AG
    Inventors: Kristen Johnson, Jian Shi
  • Patent number: 10323098
    Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: June 18, 2019
    Assignee: ROCHE GLYCART AG
    Inventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Patent number: 10323064
    Abstract: The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or treating bone diseases, including the novel peptide. The novel peptide according to the present disclosure induces mobilization of hematopoietic stem cells to blood and causes a decrease in the number of osteoclasts, and, thus, decreases bone erosion caused by osteoclasts, thereby suppressing progress of an osteoporotic lesion. Further, the novel peptide is safe since it does not cause rejection in the body. Furthermore, since the novel peptide is formed of 16 short amino acids, a low dose of the peptide can relieve symptoms of osteoporosis.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: June 18, 2019
    Assignee: Kyungpook National University Industry—Academic Cooperation Foundation
    Inventors: Jae Sung Bae, Hee Kyung Jin, Min Hee Park
  • Patent number: 10322166
    Abstract: The present invention provides compositions of matter suitable for the prevention of and/or treatment of a spinal disorder and/or spinal pain, e.g., caused by and/or associated with intervertebral disc (IVD) degeneration, and methods of treatment of a spinal disorder and/or spinal pain. For example, the compositions of the present invention comprise a modulator of growth differentiation factor (GDF)-6 signaling sufficient to reduce or prevent or delay IVD degeneration and/or to enhance or induce IVD regeneration. The present invention also provides medical devices comprising such compositions, and methods of treatment making use of such compositions.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: June 18, 2019
    Assignee: KUNOVUS PTY LTD
    Inventor: Divya Diwan
  • Patent number: 10294290
    Abstract: The present invention is based, in part, on our discovery of compositions and methods that can be used to treat a patient who has a compromised bone (due, for example, to a disease such as osteoporosis or an injury such as a bone fracture). The compositions can also be administered prophylactically. For example, they can be administered to help maintain bone health as a patient ages. More specifically, the compositions include polypeptides that constitute (or that include) a fragment of a calcitonin receptor (CR) and polypeptides that constitute (or include) biologically active variants of those fragments. Sequence-specific formulas are provided herein, and polypeptides conforming to those formulas, as well as nucleic acids encoding them, expression vectors, host cells, pharmaceutical formulations, and methods of their preparation and use are within the scope of the present invention.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: May 21, 2019
    Assignee: The Research Foundation for The State University of New York
    Inventor: Srinivas Pentyala
  • Patent number: 10294289
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: May 21, 2019
    Assignees: Therachon SAS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE NICE SOPHIA ANTIPOLIS
    Inventors: Elvire Gouze, Stéphanie Garcia
  • Patent number: 10265388
    Abstract: Systems and methods for purification and concentration of autologous alpha-2-macroglobulin (A2M) from whole blood are provided. Also provided are diagnostic methods for identifying sites in the synovial joints, spine, tendons or ligaments for treatment of pain, degeneration, or inflammation with autologous A2M. Methods for utilizing autologous A2M in combination with other autologous treatments (e.g. platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half life of the protein in joints and spine disc or epidural space.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: April 23, 2019
    Assignee: Cytonics Corporation
    Inventors: Lewis Hanna, John David Laughlin, Shawn Robert Browning
  • Patent number: 10265386
    Abstract: Implantable matrices and methods are provided. The matrices are configured to fit at or near a target tissue site, the matrices comprise biodegradable materials and ligands bound to the matrices and are configured to bind receptors and allow influx of cells into the implantable matrices, wherein the ratio of ligands to receptors is from about 1.5 to about 0.5.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: April 23, 2019
    Assignee: Warsaw Orthopedic, Inc.
    Inventor: Vanja Margareta King
  • Patent number: 10258566
    Abstract: The present invention relates to compositions, methods and kits for the treatment of bone particularly impaired or damaged bone.
    Type: Grant
    Filed: June 18, 2010
    Date of Patent: April 16, 2019
    Assignee: BIOMIMETIC THERAPEUTICS, LLC
    Inventors: Charles E. Hart, Jeffrey O. Hollinger, Samuel E. Lynch
  • Patent number: 10259878
    Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: April 16, 2019
    Assignee: APEXIGEN, INC.
    Inventors: Yongke Zhang, Xiaodong Yang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 10246499
    Abstract: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: April 2, 2019
    Assignees: Ferring B.V., Brookhaven Science Associates, LLC
    Inventors: Paul Zamora, Brent Lee Atkinson, Xinhua Lin, Louis A. Pena
  • Patent number: 10213481
    Abstract: The present invention provides pharmaceutical compositions and methods to treat inflammatory joint diseases and decrease cartilage degradation. In certain embodiments, the pharmaceutical compositions of the invention comprise an agent that binds to a ?-2,3-sialic acid transmembrane glycoprotein.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: February 26, 2019
    Inventors: Maria D. Mayan Santos, Francisco J. Blanco Garcia, Paula Carpintero Fernandez, Gary S. Goldberg
  • Patent number: 10183057
    Abstract: Methods and compositions are provided for the therapeutic use of Wnt proteins, for enhancing bone growth and regeneration, including repair following injury, osseointegration of implants, and the like. In some embodiments of the invention, the compositions are administered locally, e.g. by injection at the site of an injury. For certain conditions it is desirable to provide Wnt activity for short periods of time, and an effective dose will be administered over a defined, short period of time.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: January 22, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Jill Helms
  • Patent number: 10184009
    Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 22, 2019
    Assignee: ROCHE GLYCART AG
    Inventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Patent number: 10174088
    Abstract: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: January 8, 2019
    Assignee: Ferring B.V.
    Inventors: Paul Zamora, Brent Lee Atkinson, Xinhua Lin, Louis A. Pena
  • Patent number: 10174110
    Abstract: In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: January 8, 2019
    Assignee: Laboratoire Français du Fractionnement et des Biotechnologies
    Inventors: Harry M. Meade, Li-How Chen
  • Patent number: 10130687
    Abstract: Methods for reducing the severity of an arthritic condition or repairing an osteochondral defect are carried out by administering to a subject compositions comprising a member of the matrilin family of proteins, e.g., a matrilin protein, fragment thereof, or nucleic acid encoding the protein or fragment.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: November 20, 2018
    Assignee: Rhode Island Hospital
    Inventors: Qian Chen, Chathuraka T. Jayasuriya
  • Patent number: 10071182
    Abstract: Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived growth factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using dosing procedures leading to effective results with a minimal number of treatment applications are also described.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: September 11, 2018
    Inventors: Samuel E. Lynch, Leslie Wisner-Lynch
  • Patent number: 10059771
    Abstract: The present invention provides methods for treating nasal polyposis. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: August 28, 2018
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Leda Mannent, Gianluca Pirozzi, Allen Radin, Namita A. Gandhi, Robert Evans
  • Patent number: 10047155
    Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which bind human BMP9 and compositions and methods of use thereof.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 14, 2018
    Assignee: NOVARTIS AG
    Inventors: Zijun Chen, Sujun Deng, Yun He, Dagang Huang, Markus Kugler, Qian Li, Chris Xiangyang Lu, Xiao Luo, Yongqiang Shan, Kathrin Ulrike Tissot-Daguette, Jing Wu